IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s pipeline programs include small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development, and commercialization of more than 10 approved drugs.
IDRX-42 and IDRX-73 are both small molecule tyrosine kinase inhibitors (TKIs) designed to inhibit the key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). Our goal is for IDRX-42 to serve as a great base of therapy for GIST patients, and that when IDRX-73 is added, the combination may provide a transformative benefit.
A phase 1 study of IDRX-42 has been initiated, and is currently enrolling patients in the US and Europe. More information is available here.
Our team and founders have extensive experience in drug development, and collectively have been involved in the discovery, development and commercialization of more than 10 approved drugs.